Department of Pharmacology, Physiology, and Therapeutics, University of North Dakota School of Medicine, Grand Forks, North Dakota 58203
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Diabetic cardiomyopathy is characterized
by impaired ventricular contraction and altered function of
insulin-like growth factor I (IGF-I), a key factor for cardiac
growth and function. Endogenous IGF-I has been shown to alleviate
diabetic cardiomyopathy. This study was designed to evaluate exogenous
IGF-I treatment on the development of diabetic cardiomyopathy.
Adult rats were divided into four groups: control, control + IGF-I, diabetic, and diabetic + IGF-I. Streptozotocin
(STZ; 55 mg/kg) was used to induce experimental diabetes immediately
followed by a 7-wk IGF-I (3 mg · kg1 · day
1 ip)
treatment. Mechanical properties were assessed in ventricular myocytes
including peak shortening (PS), time-to-PS (TPS), time-to-90% relengthening (TR90) and maximal velocities of
shortening/relengthening (±dL/dt). Intracellular
Ca2+ transients were evaluated as Ca2+-induced
Ca2+ release and Ca2+ clearing constant. Levels
of sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA),
phospholamban (PLB), and glucose transporter (GLUT4) were assessed by
Western blot. STZ caused significant weight loss and elevated blood
glucose, demonstrating the diabetic status. The diabetic state is
associated with reduced serum IGF-I levels, which were restored by
IGF-I treatment. Diabetic myocytes showed reduced PS and
±dL/dt as well as prolonged TPS, TR90, and intracellular Ca2+ clearing compared with control.
IGF-I treatment prevented the diabetes-induced abnormalities in PS,
±dL/dt, TR90, and Ca2+ clearing but
not TPS. The levels of SERCA and GLUT4, but not PLB, were significantly
reduced in diabetic hearts compared with controls. IGF-I treatment
restored the diabetes-induced decline in SERCA, whereas it had no
effect on GLUT4 and PLB levels. These results suggest that exogenous
IGF-I treatment may ameliorate contractile disturbances in
cardiomyocytes from diabetic animals and could provide therapeutic
potential in the treatment of diabetic cardiomyopathy.
diabetic cardiomyopathy; insulin-like growth factor I; ventricular myocytes; sarco(endo)plasmic reticulum Ca2+-ATPase; glucose transporter 4
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
DIABETES IS A MAJOR RISK FACTOR leading to increased cardiovascular mortality and morbidity (19, 40). Accumulating evidence has demonstrated the existence of a specific cardiomyopathy associated with diabetes. The myopathy occurs independently of micro/macrovascular changes and contributes significantly to death in the diabetic population (17, 19). Diastolic dysfunction is the most prominent defect of diabetic cardiomyopathy, manifested by decreased compliance, prolonged myocardial relaxation, and altered intracellular Ca2+ homeostasis (17, 32, 33). Recent studies suggest that diabetic cardiomyopathy may be directly due to impaired mechanical function at the single ventricular myocyte level in both chemically induced and genetically predisposed experimental diabetic models (32, 33, 36).
Insulin-like growth factor I (IGF-I) is an important growth factor for cell differentiation and proliferation (12, 35, 38). It is produced in the heart as well as other tissues and acts as both an autocrine and a paracrine hormone. Its main function in the heart is to stimulate cardiac growth and contractile function (10, 35). IGF-I has been shown to stimulate protein synthesis, increase inositol 1,4,5-trisphosphate levels, activate tyrosine kinase, tyrosine kinase phosphatase, phosphatidylinositol 3-kinase, and protein kinase C, and enhance myocardial contraction and intracellular Ca2+ sensitivity (9, 15, 35, 41). Approximately 95% of circulating IGF-I is bound to IGF-I-binding proteins (IGFBPs), predominantly IGFBP-3, which are believed to modulate the actions of IGF-I in a cellular-specific manner (12). Although free IGF-I has a relatively short half-life (~15 min), factors like IGFBPs may extend the actual half-life of IGF-I in the body to ~10 h (7). IGF-I and IGFBP levels are reduced in diabetes, possibly as a result of insufficient portal insulinization and hepatic growth hormone resistance (3, 5). The reduced IGF-I and IGFBP levels in diabetes raise the possibility that this pathway may contribute to the pathogenesis of diabetic cardiomyopathy. Clinically, IGF-I has been used as a replacement for insulin to facilitate glucose transport and metabolism in diabetes, especially under insulin-resistant conditions (1, 27). Combined treatment with IGF-I and insulin in diabetic patients was reported to correct growth hormone hypersecretion, improve insulin sensitivity and glucose control, and decrease the requirement for insulin (39). Our laboratory has recently shown that diabetic cardiomyopathy may be prevented with insulin-sensitizing antidiabetics such as metformin (34). Others have shown that cardiac overexpression of IGF-I inhibits the development of diabetic cardiomyopathy (23). Exogenously administered IGF-I has been shown to have both positive (16) and negative (31) effects on the development of cardiac disorders such as heart failure. However, the impact of exogenous IGF-I administration on diabetes-associated cardiac contractile dysfunction is largely unknown.
Although transgenic overexpression of IGF-I reverses diabetic cardiomyopathy in mice (23), it has not been used clinically for this purpose. To evaluate the therapeutic potential of exogenous IGF-I administration in diabetic cardiomyopathy, we determined the impact of exogenous IGF-I administration on diabetes-induced impairment in cardiac excitation-contraction (E-C) coupling by using state-of-the-art video-based edge detection and intracellular Ca2+ recording in isolated ventricular myocytes. Because mechanical dysfunction that characterizes diabetic cardiomyopathy is associated with changes in intracellular Ca2+ regulation and glucose transport (13, 18, 26, 28, 30), the impact of IGF-I treatment on the abundance of sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA), phospholamban (PLB), and GLUT4 was assessed by Western blotting.
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Experimental animals and assay for IGF-I and glucose.
All animal experimentation was conducted in accordance with humane
animal care standards outlined in the National Institutes of Health
Guide for the Care and Use of Experimental Animals and approved by the
Animal Investigation Committee of the University of North Dakota School
of Medicine. Briefly, 6-wk-old male Sprague-Dawley (SD) rats (Harlan
Sprague Dawley, Indianapolis, IN) were made diabetic with a single
intravenous tail vein injection of streptozotocin (STZ; 55 mg/kg iv),
as described (33), and maintained for 7 wk of untreated
diabetes. A group of vehicle-treated, age-matched euglycemic rats was
selected in parallel with the STZ-treated rats. IGF-I (Genentech,
San Francisco, CA, and National Hormone and Peptide Program, National
Institute of Diabetes and Digestive and Kidney Diseases) was
supplemented for 7 wk (3 mg · kg1 · day
1 ip). Saline
was used in the non-IGF-I treatment groups. The diabetic state was
assessed by weekly measurement of the glucose level by means of an
Accu-ChekII glucometer (model 792, Boehringer Mannheim Diagnostics,
Indianapolis, IN). At the time animals were killed, plasma was
collected, and plasma total IGF-I levels were determined using an
ELISA commercial kit from Diagnostic System Laboratory (Webster, TX).
Isolation of ventricular myocytes. Single ventricular myocytes were enzymatically isolated from hearts by use of the method described previously (44). Briefly, hearts were rapidly removed and perfused (at 37°C) with Krebs-Henseleit bicarbonate (KHB) buffer containing (in mM) 118 NaCl, 4.7 KCl, 1.25 CaCl2, 1.2 MgSO4, 1.2 KH2PO4, 25 NaHCO3, 10 N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES) and 11.1 glucose, equilibrated with 5%CO2-95% O2. Hearts were subsequently perfused with a nominally Ca2+-free KHB buffer for 2-3 min until spontaneous contractions ceased, followed by a 20-min perfusion with Ca2+-free KHB containing 223 U/ml collagenase (Worthington Biochemical, Freehold, NJ) and 0.1 mg/ml hyaluronidase (Sigma Chemical, St. Louis, MO). After perfusion, ventricles were removed and minced, under sterile conditions, and incubated with the calcium-free KHB with collagenase solution for 3-5 min. The cells were further digested with 0.02 mg/ml trypsin (Sigma) before being filtered through a nylon mesh (300 µm) and subsequently separated from the collagenase-trypsin solution by centrifugation (60 g for 30 s). Myocytes were resuspended in a sterile-filtered, Ca2+-free Tyrode's buffer containing (in mM) 131 NaCl, 4 KCl, 1 MgCl2, 10 HEPES, and 10 glucose, supplemented with 2% bovine serum albumin, pH 7.4, at 37°C. Cells were initially washed with Ca2+-free Tyrode's buffer to remove residual enzyme, and extracellular Ca2+ was slowly added back to 1.25 mM. Only rod-shaped myocytes with clear edges were selected for recording of mechanical properties, as previously described (44).
Cell shortening/relengthening. Mechanical properties of ventricular myocytes were assessed using a video-based, edge detection system (IonOptix, Milton, MA) (44). In brief, cells were placed in a Warner chamber mounted on the stage of an inverted microscope (Olympus, IX-70) and superfused (~1 ml/min at 30°C) with a buffer containing (in mM) 131 NaCl, 4 KCl, 1 CaCl2, 1 MgCl2, 10 glucose, and 10 HEPES, pH 7.4. Cells were field stimulated with suprathreshold voltage and at a frequency of 0.5 Hz, unless otherwise defined, for 3 ms duration with a pair of platinum wires placed on opposite sides of the chamber connected to an FHC stimulator (Brunswick, NE). The polarity of stimulatory electrodes was reversed frequently to avoid possible build-up of electrolyte byproducts. The myocyte being studied was displayed on the computer monitor by means of an IonOptix MyoCam camera, which rapidly scans the image area at every 8.3 ms such that the amplitude and velocity of shortening/relengthening are recorded with good fidelity. The Soft-Edge software (IonOptix) was used to capture changes in cell length during shortening and relengthening.
Intracellular Ca2+ transient
measurement.
Intracellular fluorescence properties were measured using a
dual-excitation, single-emission photomultiplier system (IonOptix) in
myocytes loaded with fura 2-AM (0.5 µM). Myocytes were placed on an
inverted microscope and imaged through an Olympus (model: IX-70) Fluor
×40 oil objective. Myocytes were exposed to light emitted by a 75-W
halogen lamp through either a 360- or 380-nm filter while being
stimulated to contract at 0.5 Hz. Fluorescence emissions were detected
between 480 and 520 nm by a photomultiplier tube after initial
illumination at 360 nm for 0.5 s and then at 380 nm for the
duration of the recording protocol. The 360-nm excitation reading was
repeated at the end of the protocol. Qualitative evaluation of the
electrically stimulated Ca2+-induced Ca2+
release was inferred from the fura fluorescence intensity changes. A
Chebyshev curve-fitting technique was used to evaluate the
intracellular Ca2+ clearing or decay kinetics to calculate
the intracellular Ca2+ decay constant (, the duration
for 2/3 Ca2+ transient decay from peak). The
goodness of fit was confirmed by visually inspecting the fitted curve
to the actual data. Deviations were not accepted (32).
Myocyte shortening was also evaluated in a cohort of the fura 2-loaded
ventricular myocytes simultaneously to compare their temporal
relationship with the fluorescence signal. However, their mechanical
properties (although quite similar to those from the nonloaded cells)
were not used for data summary due to the Ca2+ buffering
effect of fura 2 (44).
Western analysis of SERCA2, PLB, and GLUT4. Membrane proteins from the left ventricular myocardium of each heart were isolated as described (18). Freshly dissected hearts were homogenized and centrifuged at 1,000 g for 10 min. The supernatants were centrifuged at 70,000 g for 30 min at 4°C. The 100,000-g pellets were cellular membrane fractions and were used for immunoblotting of SERCA2, PLB, and GLUT4. We confirmed that these membrane fractions did not contain any detectable collagens. Membrane proteins (50 µg/lane) were separated on 7% (SERCA2a) or 15% (PLB and GLUT4) SDS-polyacrylamide gels in a minigel apparatus (Mini-PROTEAN II, Bio-Rad) and transferred to polyvinylidene difluoride membranes. The membranes were blocked (4% Block Ace, Dainippon Pharmaceutical, Osaka, Japan) and then incubated with anti-SERCA2 (1:1,000 dilution), anti-PLB (1:1,000), and anti-GLUT4 (1:4,000) antibodies [monoclonal antibodies to SERCA2a (A7R5) and PLB (2D12) were kindly provided by Dr. Larry Jones, Indiana University School of Medicine]. GLUT4 monoclonal antibody was purchased from Chemicon International (Temecula, CA). The antigens were detected by the enhanced luminescence method (ECL Western blotting detection kit, Amersham) with peroxidase-linked anti-mouse (SERCA2a and PLB) or anti-rabbit (GLUT4) IgG (1:5,000 dilution). After immunoblotting, the film was scanned, and the intensity of immuoblot bands was detected with a Bio-Rad calibrated densitometer (model GS-800).
Statistical analyses. For each experimental series, data are presented as means ± SE. Statistical significance (P < 0.05) for each variable was estimated by analysis of variance (ANOVA) or t-test, where appropriate (SYSTAT, Evanston, IL). A Dunnett's test was used for post hoc analysis.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
General features of experimental animals.
Chronic diabetes induced severe deficiency in serum IGF-I levels,
which was restored by exogenous IGF-I administration. The diabetic
animals exhibited significantly reduced body weight gain and higher
blood glucose levels compared with their age-matched nondiabetic
controls. Diabetic animals displayed decreased heart weight; however,
the liver and kidney weights were not significantly affected compared
with the age-matched controls. Exogenous IGF-I administration did
not significantly affect the biometric indexes in either diabetic or
control groups (Table 1).
|
Cell shortening and relengthening in cardiac myocytes.
Peak shortening (PS) amplitude normalized to cell length was
significantly decreased in ventricular myocytes under STZ-induced diabetes. Myocytes from the diabetic group also demonstrated
significantly prolonged time-to-peak shortening (TPS) and time-to-90%
relengthening (TR90) compared with control, consistent with
our previous findings (33, 34). IGF-I administration
completely abolished the diabetes-induced abnormalities of PS and
TR90 but did not affect TPS. None of these mechanical
indexes (PS, TPS, TR90) was affected by IGF-I
administration in the control group (Fig.
1, A-D). The maximal
velocities of shortening (+dL/dt) and relengthening
(dL/dt) were significantly reduced by diabetes; however,
IGF-I partially restored the diabetes-induced decrease in
±dL/dt (Fig. 2, A
and B). In addition, IGF-I administration did not affect
+dL/dt but attenuated
dL/dt in the control
group.
|
|
Effect of IGF-I administration on intracellular
Ca2+ transients.
To evaluate whether the IGF-I-induced beneficial effects on
diabetic cardiomyopathy were due to its effect on intracellular Ca2+ homeostasis, intracellular Ca2+ transients
were evaluated in fura 2-loaded myocytes. Myocytes from diabetic
animals showed reduced baseline Ca2+ and electrically
stimulated Ca2+-induced Ca2+ release levels
compared with those from the control group. Intracellular Ca2+ decay constant () was significantly elevated in
diabetes, indicating a slowed Ca2+ extrusion rate.
Consistent with its effect on TR90, IGF-I
administration ablated the diabetes-induced abnormal intracellular
Ca2+ clearing. Finally, IGF-I administration itself
decreased resting intracellular Ca2+ levels in the control
group (Fig. 3, A-C).
|
Effect of extracellular Ca2+ on
myocyte shortening.
To examine the influence of extracellular Ca2+ levels on PS
amplitude, myocytes were first stimulated to contract at 0.5 Hz in a
contractile buffer defined in MATERIALS AND METHODS with 0.5 mM CaCl2. After the steady-state PS had been recorded,
the extracellular Ca2+ level was increased to 1.0, 2.0, and
3.0 mM, with a 5-min interval between each concentration. Figure
4 shows that the PS amplitude was
significantly depressed in the diabetic myocytes under 0.5 mM
extracellular Ca2+ concentration, consistent with the
results obtained at 1.0 mM extracellular Ca2+ (Fig. 1).
Increases in extracellular Ca2+ concentration from 0.5 to 3 mM resulted in a positive staircase (although not at 3 mM) in PS
amplitude in myocytes from the control group. Diabetes significantly
shifted the Ca2+ concentration-response curve downward,
which was partially prevented by IGF-I administration. IGF-I
administration did not significantly affect the Ca2+
response curve in the control group (data not shown). These data may
suggest a possible alteration in myocyte responsiveness to Ca2+ in diabetes, which has been reported previously in
both chemically induced and genetically predisposed diabetic models
(22, 32).
|
Effect of stimulation frequency on myocyte shortening.
Rat hearts normally contract at very high frequencies (300 beats/min or
5 Hz), whereas our baseline studies were conducted at 0.5 Hz. To assess
for possible derangement of cardiac E-C coupling at higher frequencies,
we increased the stimulating frequency up to 5 Hz and recorded
steady-state peak shortening. Cells were initially stimulated to
contract at 0.5 Hz for 5 min to ensure steady state before the
frequency study commenced. All recordings were normalized to PS at 0.1 Hz of the same myocyte. Figure 5 shows a
negative staircase in PS with increasing stimulation frequency. The
pattern of response was comparable between the diabetic and control
groups. However, myocytes from the control + IGF-I group displayed a significantly higher rate of decline in PS when stimulatory frequency was increased from 0.1 to 0.5 Hz (PS at 0.1 Hz was normalized to 100%). Changes in the stimulating frequency from 0.1 to 5 Hz did
not affect the prolongation in either TPS or TR90 in
diabetic rats (data not shown).
|
Western blotting of SERCA2, PLB, and GLUT4.
The protein levels of SERCA2, PLB, and GLUT4 from hearts of control and
diabetic rats with or without IGF-I treatment are shown in Fig.
6. Consistent with previous reports
(13, 18, 26), both SERCA2 and GLUT4 protein levels were
significantly reduced, whereas PLB was unchanged in STZ-induced
diabetic hearts compared with the control group. IGF-I
supplementation did not affect GLUT4 and PLB levels in either control
or diabetic group. Interestingly, the diabetes-induced decline in
SERCA2 level was restored by the 7-wk IGF-I treatment. IGF-I
supplementation also significantly enhanced the SERCA2 level in
the control hearts. These observations are consistent with the
functional data of improved intracellular Ca2+ clearing and
duration of relengthening (TR90) with IGF-I treatment.
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The major findings from our study demonstrated that exogenous IGF-I treatment inhibits the development of certain characteristics of diabetic cardiomyopathy such as abnormal E-C coupling in isolated ventricular myocytes. Our results revealed decreased myocyte PS, reduced ±dL/dt, and markedly prolonged duration of shortening and relengthening in myocytes from STZ-induced diabetic hearts. These mechanical abnormalities may be underscored by altered intracellular Ca2+ homeostasis, shown as slowed intracellular Ca2+ removal, reduced resting intracellular Ca2+ levels, and Ca2+-induced Ca2+ release. Our immunostaining study indicated that the impaired intracellular Ca2+ homeostasis may be associated with a reduction in the main Ca2+-regulating protein SERCA and/or indirectly with metabolic derangement due to the compromised membrane glucose transporter GLUT4 under the diabetic state, consistent with earlier observations (13, 18, 26, 28). Interestingly, these diabetes-induced cardiac mechanical dysfunctions (except prolonged TPS) were significantly inhibited by daily exogenous IGF-I treatment, supporting a recent report using endogenous transgenic overexpression of IGF-I (23). Our study also indicated that IGF-I treatment may protect against a diabetes-induced decline in cardiac SERCA2 but not GLUT4 protein abundance. These observations make IGF-I of potential interest for the treatment of diabetes-induced cardiac myopathic complications.
In this study, STZ-treated rats developed typical signs of diabetes,
such as hyperglycemia and growth retardation associated with severely
reduced plasma IGF-I levels. The hyperglycemic status in STZ rats
was not affected by exogenous IGF-I treatment, which is in line
with the lack of effect of IGF-I on GLUT4 levels. Reduction in
GLUT4 in the diabetic heart is likely due to hyperglycemia as opposed
to lack of insulin (13, 18). A recent study found that
mice with cardiac-specific knockout of the insulin receptor actually
have increased cardiac GLUT4 content (2). The metabolic efficacy of IGF-I is only 6-10% of that of insulin (6,
20). Although administration of IGF-I was shown to reduce
blood glucose (27, 46), conflicting observations have also
been reported (15, 23, 42). The inconsistency in the
glucose metabolic properties of IGF-I may be related to the manner
of administration, timing of IGF-I injection, and glucose
measurement. Data from our study confirmed the previous findings that
sustained diabetes leads to severe loss of IGF-I (3,
5), possibly due to insufficient portal insulinization and
hepatic growth hormone resistance in diabetes. Interestingly, our
exogenous IGF-I administration regimen was able to restore >70%
of the IGF-I under the diabetic condition. Because the dose of
IGF-I administration (3 mg · kg1 · day
1) is
relatively high (15, 16), it may be speculated that the diabetes-induced decrease in the level of IGFBPs may not be able to
provide enough "reservoir" capacity, even though they may be "upregulated" by IGF-I administration (42).
The present study revealed decreased PS and
±dL/dt, associated with prolonged TPS and
TR90 in myocytes from diabetic hearts, consistent
with the hallmarks of diabetic cardiomyopathy reported previously in
whole heart (11), papillary muscle (36), and isolated myocytes (32, 33, 44). Our present observation of
a reduced intracellular Ca2+-clearing constant (higher value) associated with a reduced resting intracellular Ca2+
level as well as Ca2+-induced Ca2+ release in
myocytes from diabetic hearts is also similar to earlier published
findings (32, 33, 36) and is believed to be responsible for the impaired mechanical function in myocytes. The reduced intracellular Ca2+ transient decay is consistent with the
prolonged TR90 and may be a result of impaired SERCA and/or
Na+/Ca2+ exchange in diabetes, consistent with
our immunostaining result and earlier reports (8, 26). On
the other hand, the reduced resting Ca2+ level and
Ca2+-induced Ca2+ release, which correlate with
reduced PS and ±dL/dt, may have resulted from
diabetes-induced reduction in membrane Ca2+ channel
conduction and sarcoplasmic reticulum Ca2+ load (8,
30, 43). In addition, several other factors have also been
speculated to contribute to the diabetes-induced cardiac mechanical
dysfunctions such as alterations in
Ca2+-calmodulin-dependent protein kinase (30),
myosin isozyme switch (from V1 to V3)
(14), and myofilament Ca2+ sensitivity
(22, 32). Changes in the contractile apparatus would
affect not only cardiac contractility (PS) but also the velocity of
contraction (+dL/dt), which may subsequently manipulate the duration of contraction (TPS). Myosin isozyme switch has been shown
to lead directly to a decrease in Ca2+ responsiveness
(29) and may be responsible for the depressed myofilament
Ca2+ sensitivity in diabetes (22, 25). This is
supported by the observation from the present study that myocyte
shortening in response to increased extracellular Ca2+
concentration (0.5-3 mM) is clearly diminished in the diabetic group compared with the control group. Because SERCA contributes to
~92% of the cytosolic Ca2+ removal workload in rat
hearts (4), our finding of an overt reduction in SERCA2a
protein level in STZ-induced diabetic hearts should have provided one
of the most compelling explanations for the slowed intracellular
Ca2+ clearing and prolonged duration of relaxation
(TR90). PLB is the main inhibitor of SERCA, acting to keep
SERCA function "in check." An increase in the PLB-to-SERCA2
ratio reduces the SERCA Ca2+ affinity and activity, leading
to prolonged relaxation and a reduced contractility. On the other hand,
a decreased PLB-to-SERCA2 ratio improves the cardiac Ca2+
cycling and pumping function (28). Our results clearly
show an enhanced PLB-to-SERCA2 ratio in diabetic hearts, consistent with the prolonged
/TR90 and reduced PS. More
importantly, results from our study indicated that exogenous IGF-I
treatment prevented the slowed intracellular Ca2+ clearing,
which may underscore its protective effect on prolonged relaxation
(TR90) in diabetes. This was nicely associated with the
ability of exogenous IGF-I treatment to restore the PLB-to-SERCA2 ratio to the control level, providing a plausible explanation for its
ability to prevent diabetes-induced defects in PS,
, and
TR90. The significance of the PLB-to-SERCA2 ratio on
myocardial contractile regulation has been demonstrated in rodent
models with variable expression levels of PLB and SERCA
(28).
In our study, certain diabetes-induced mechanical defects were not improved or protected by exogenous IGF-I treatment. For example, IGF-I improved the diabetes-induced reduction in PS but not Ca2+-induced Ca2+ release. Although the underlying mechanism is largely unknown, the ability of IGF-I to enhance myofilament Ca2+ sensitivity (9) may play a role. This is somewhat supported by the results shown in Fig. 4, where myocytes from the diabetic + IGF-I group exhibit an improved PS at low (<1 mM) extracellular Ca2+ levels compared with the myocytes from the diabetic group. However, an additional increase in extracellular Ca2+ level (to 3 mM) failed to induce a further increase in PS within the diabetic + IGF-I group. The mechanism of action is unknown, although a potential "saturating" effect of IGF-I on myofilament Ca2+ sensitivity may be speculated. In addition, potential involvement of Ca2+-independent mechanisms should not be excluded at this time. Second, results from this study revealed that exogenous IGF-I administration lowered the resting intracellular Ca2+ levels in the nondiabetic group but did not affect the already reduced resting intracellular Ca2+ levels in myocytes from the diabetic group. This IGF-I-induced reduction in resting intracellular Ca2+ level may be associated with an enhanced SERCA Ca2+ clearing ability in the control + IGF-I group (Fig. 6) and is consistent with the vasodilatory and cardioprotective effect against Ca2+ overload under pathological conditions such as heart failure (15, 38). Third, the frequency-PS relationship was not affected by diabetes (Fig. 5), indicating a preserved sarcoplasmic reticulum (SR)-replenishing function in diabetic hearts. However, IGF-I treatment caused a steeper decline of the frequency-PS curve in the control group but not in the diabetic group. One possible explanation is that IGF-I may significantly augment the basal SR Ca2+ load (at 0.1 Hz) in the control group, which may be offset by diabetes (30). It may also reflect an adverse effect of IGF-I treatment. Further study is warranted to determine the effect of IGF-I on SR Ca2+ load and replenishing capacity. Last, but not least, the lack of effect of IGF-I treatment on TPS indicates that IGF-I may not have any significant effect on the key rate-limiting components determining the length of contraction duration such as SR Ca2+ release, troponin, tropomyosin, and actin-myosin cross-bridge linking.
Using the IGF-I transgene technique, Anversa's group [Kajstura et al. (23) and Kerr et al. (24)] recently showed that cardiac-specific IGF-I overexpression not only improves cardiac contractile function but also offers protection against oxidative stress, apoptosis, and, ultimately, diabetic cardiomyopathy. Our present study revealed beneficial effects of IGF-I even in the presence of persistent hyperglycemia, thus excluding any role of glucose metabolism in IGF-I-induced cardiac protection. IGF-I is ~10 times more potent than insulin in modulating the cardiac function (9, 36) and is capable of improving the sensitivity of insulin (35), which is severely deficient in STZ-induced diabetes (21). These inotropic properties of IGF-I may have provided the therapeutic advantage of IGF-I over insulin (or their use in combination) in the management of compromised heart function under diabetes. Another point worth mentioning is that IGF-I administration may enhance sympathetic catecholamine release, thus improving cardiac function (15). However, this is not likely to be the scenario for enhanced ventricular myocyte mechanics under our in vitro condition, because limited catecholamines would be available. Our present study adds to the growing body of data supporting the prophylactic and interventional use of IGF-I treatment for cardiac complications such as diabetic cardiomyopathy and congestive heart failure via direct beneficial actions on survival and function of ventricular myocytes (35, 38). However, caution must be used when interpreting data from our current cellular study, since in vivo cardiac function evaluation (such as echocardiograph) was not provided.
Although accumulating evidence, including the present study, has shown a beneficial effect of IGF-I on cardiac function, the use of exogenous IGF-I treatment in cardiovascular diseases may be hampered by the systemic adverse effects associated with IGF-I, ranging from dizziness, fatigue, palpitations, and flushing to dyspnea or even transient cerebral dysfunction (37). These events often occur during acute intravenous infusion with a high dose of IGF-I. On the other hand, due to the growth-stimulating properties of IGF-I, extremely prolonged use may also be associated with unwanted growth promotion such as atherosclerosis. Administration of exogenous IGF-I has been shown to stimulate an increase in circulating IGFBP levels, although this increase may be insufficient to alter the IGF-I binding capacity (45). However, the potential alteration of IGFBP levels due to exogenous IGF-I administration, which was not examined in our study, may be an important drawback for the exogenous IGF-I treatment, since IGFBPs are known to affect the biologically active fraction of IGF-I, or free IGF-I. Further understanding of the specific cardiac pathways modulated by IGF-I and IGFBPs may help us design a useful treatment regimen for diabetic cardiomyopathy and other cardiac complications.
In conclusion, our findings provide evidence that impaired cardiac E-C coupling in diabetes is significantly improved by exogenous IGF-I administration, probably by improved intracellular Ca2+ homeostasis and Ca2+-regulating protein function such as SERCA. Given what we know about the ability of IGF-I to promote cell survival and cardiac performance (35, 38), the in-depth mechanism of action and clinical value of employing IGF-I in the prevention and treatment of diabetic cardiomyopathy warrant further investigation.
![]() |
ACKNOWLEDGEMENTS |
---|
We thank Nicholas S. Aberle II, Jamie R. Privratsky, Grant E. McFadden, Bonnie H. Ren, and the staff of the Center for Biomedical Research at University of North Dakota for their expert technical assistance.
![]() |
FOOTNOTES |
---|
This work was supported in part by grants from the American Diabetes Association to J. Ren. F. L. Norby and K. K. Hintz were supported in part by the North Dakota Experimental Program to Stimulate Competitive Research (EPSCoR) science-bound program. IGF-I was obtained from Genentech (South San Francisco, CA) and Dr. A. F. Parlow, National Hormone and Peptide Program, National Institute of Diabetes and Digestive and Kidney Diseases.
Address for reprint requests and other correspondence: J. Ren, Dept. of Pharmacology, Physiology, and Therapeutics, Univ. of North Dakota School of Medicine, 501 N. Columbia Rd., Grand Forks, ND 58203 (E-mail: jren{at}medicine.nodak.edu).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
June 25, 2002;10.1152/ajpendo.00003.2002
Received 7 January 2002; accepted in final form 19 June 2002.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Asada, T,
Ogawa T,
Iwai M,
and
Kobayashi M.
Effect of recombinant human insulin-like growth factor-I on expression of glucose transporters, GLUT 2 and GLUT 4, in streptozotocin-diabetic rat.
Jpn J Pharmacol
78:
63-67,
1998[ISI][Medline].
2.
Belke, DD,
Betuing S,
Tuttle MJ,
Graveleau C,
Young ME,
Pham M,
Zhang D,
Cooksey RC,
McClain DA,
Litwin SE,
Taegtmeyer H,
Severson D,
Kahn CR,
and
Abel ED.
Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression.
J Clin Invest
109:
629-639,
2002
3.
Bereket, A,
Lang CH,
and
Wilson TA.
Alterations in the growth hormone-insulin-like growth factor axis in insulin dependent diabetes mellitus.
Horm Metab Res
31:
172-181,
1999[ISI][Medline].
4.
Bers, DM.
Cardiac excitation-contraction coupling.
Nature
415:
198-205,
2002[ISI][Medline].
5.
Bornfeldt, KE,
Skottner A,
and
Arnqvist HJ.
In-vivo regulation of messenger RNA encoding insulin-like growth factor-I (IGF-I) and its receptor by diabetes, insulin and IGF-I in rat muscle.
J Endocrinol
135:
203-211,
1992[Abstract].
6.
Boulware, SD,
Tamborlane WV,
Rennert NJ,
Gesundhei N,
and
Sherwin RS.
Comparison of metabolic effects of recombinant human IGF-I and insulin.
J Clin Invest
93:
1131-1139,
1994[ISI][Medline].
7.
Bucuvalas, JC,
Chernausek SD,
Alfaro MP,
Krug SK,
Ritschel W,
and
Wilmott RW.
Effect of insulin-like growth factor-1 treatment in children with cystic fibrosis.
J Pediatr Gastroenterol Nutr
33:
576-581,
2001[ISI][Medline].
8.
Chattou, S,
Diacono J,
and
Feuvray D.
Decrease in sodium-calcium exchange and calcium currents in diabetic rat ventricular myocytes.
Acta Physiol Scand
166:
137-144,
1999[ISI][Medline].
9.
Cittadini, A,
Ishiguro Y,
Stromer H,
Spindler M,
Moses AC,
Clark R,
Douglas PS,
Ingwall JS,
and
Morgan JP.
Insulin-like growth factor-1 but not growth hormone augments mammalian myocardial contractility by sensitizing the myofilament to Ca2+ through a wortmannin-sensitive pathway: studies in rat and ferret isolated muscles.
Circ Res
83:
50-59,
1998
10.
Cittadini, A,
Stromer H,
Katz SE,
Clark R,
Moses AC,
Morgan JP,
and
Douglas PS.
Differential cardiac effects of growth hormone and insulin-like growth factor-1 in the rat: a combined in vivo and in vitro evaluation.
Circulation
93:
800-809,
1996
11.
Davidoff, AJ,
Pinault FM,
and
Rodgers RL.
Ventricular relaxation of diabetic spontaneously hypertensive rat.
Hypertension
15:
643-651,
1990[Abstract].
12.
Delafontaine, P.
Insulin-like growth factor I and its binding proteins in the cardiovascular system.
Cardiovasc Res
30:
825-834,
1995[ISI][Medline].
13.
Depre, C,
Young ME,
Ying J,
Ahuja HS,
Han Q,
Garza N,
Davies PJ,
and
Taegtmeyer H.
Streptozotocin-induced changes in cardiac gene expression in the absence of severe contractile dysfunction.
J Mol Cell Cardiol
32:
985-996,
2000[ISI][Medline].
14.
Dillmann, WH.
Diabetes and thyroid-hormone-induced changes in cardiac function and their molecular basis.
Annu Rev Med
40:
373-394,
1989[ISI][Medline].
15.
Donath, MY,
Sutsch G,
Yan X-W,
Piva B,
Brunner H-P,
Glatz Y,
Zapf J,
Follath F,
Froesch ER,
and
Kiowski W.
Acute cardiovascular effects of insulin-like growth factor I in patients with chronic heart failure.
J Clin Endocrinol Metab
83:
3177-3183,
1998
16.
Duerr, RL,
McKirnan MD,
Gim RD,
Clark RG,
Chien KR,
and
Ross J, Jr.
Cardiovascular effects of insulin-like growth factor-I and growth hormone in chronic left ventricular failure in the rat.
Circulation
93:
2188-2196,
1996
17.
Fein, FS,
Strobeck JE,
Malhotra A,
Scheuer J,
and
Sonnenblick EH.
Reversibility of diabetic cardiomyopathy with insulin in rats.
Circ Res
49:
1251-1261,
1981[Abstract].
18.
Garvey, WT,
Hardin D,
Juhaszova M,
and
Dominguez JH.
Effects of diabetes on myocardial glucose transport system in rats: implications for diabetic cardiomyopathy.
Am J Physiol Heart Circ Physiol
264:
H837-H844,
1993
19.
Grundy, SM,
Benjamin IJ,
Burke GL,
Chaiot A,
Eckel RH,
Howrda BV,
Mitch W,
Smith SC,
and
Sowers JR.
Diabetes and cardiovascular disease. A statement for healthcare professionals from the American Heart Association.
Circulation
100:
1134-1146,
1999
20.
Guler, HP,
Zapf J,
and
Froesch ER.
Short term metabolic effects of recombinant IGF-I in healthy adults.
N Engl J Med
317:
137-140,
1987[Abstract].
21.
Heyliger, CE,
Prakash A,
and
McNeill JH.
Alterations in cardiac sarcolemmal Ca2+ pump activity during diabetes mellitus.
Am J Physiol Heart Circ Physiol
252:
H540-H544,
1987
22.
Hofmann, PA,
Menon V,
and
Gannaway KF.
Effects of diabetes on isometric tension as a function of [Ca2+] and pH in rat skinned cardiac myocytes.
Am J Physiol Heart Circ Physiol
269:
H1656-H1663,
1995
23.
Kajstura, J,
Fiordaliso F,
Andreoli AM,
Li B,
Chimenti S,
Medow MS,
Limana I,
Nadal-Ginard B,
Leri A,
and
Anversa P.
IGF-I overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II-mediated oxidative stress.
Diabetes
50:
1414-1424,
2001
24.
Kerr, D,
Tamborlane WV,
Rife F,
and
Sherwin RS.
Effect of insulin-like growth factor-1 on the responses to and recognition of hypoglycemia in humans. A comparison with insulin.
J Clin Invest
91:
141-147,
1993[ISI][Medline].
25.
Khandoudi, N,
Guo AC,
Chesnais M,
and
Feuvray D.
Skinned cardiac fibres of diabetic rats: contractile activation and effects of 2,3-butanedione monoxime (BDM) and caffeine.
Cardiovasc Res
27:
447-452,
1993[ISI][Medline].
26.
Kim, HW,
Ch YS,
Lee HR,
Park SY,
and
Kim YH.
Diabetic alterations in cardiac sarcoplasmic reticulum Ca2+-ATPase and phospholamban protein expression.
Life Sci
70:
367-379,
2001[ISI][Medline].
27.
Kolaczynski, JW,
and
Caro JF.
Insulin-like growth factor I therapy for diabetes mellitus?
Diabetes Care
17:
92-96,
1994[ISI][Medline].
28.
Koss, KL,
Grupp IL,
and
Kranias EG.
The relative phospholamban and SERCA2 ratio: a critical determinant of myocardial contractility.
Basic Res Cardiol
2:
17-24,
1997.
29.
Metzger, JM,
Wahr PA,
Michele DE,
Albayya F,
and
Westfall MV.
Effects of myosin heavy chain isoform switching on Ca2+-activated tension development in single adult cardiac myocytes.
Circ Res
84:
1310-1317,
1999
30.
Netticadan, T,
Temsah RM,
Kent A,
Elimban V,
and
Dhalla NS.
Depressed levels of Ca2+-cycling proteins may underlie sarcoplasmic reticulum dysfunction in the diabetic heart.
Diabetes
50:
2133-2138,
2001
31.
Osterziel, KJ,
Strohm O,
Schuler J,
Friedrich M,
Hanlein D,
Willenbrock R,
Anker SD,
Poole-Wilson PA,
Ranke MB,
and
Dietz R.
Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy.
Lancet
351:
1233-1237,
1998[ISI][Medline].
32.
Ren, J,
and
Bode AM.
Altered cardiac excitation-contraction coupling in ventricular myocytes from spontaneously diabetic BB rats.
Am J Physiol Heart Circ Physiol
279:
H238-H244,
2000
33.
Ren, J,
and
Davidoff AJ.
Diabetes rapidly induces contractile dysfunctions in isolated ventricular myocytes.
Am J Physiol Heart Circ Physiol
272:
H148-H158,
1997
34.
Ren, J,
Dominguez LJ,
Sowers JR,
and
Davidoff AJ.
Metformin but not glyburide prevents high [glucose]-induced abnormalities in relaxation and intracellular Ca2+ in rat ventricular myocytes.
Diabetes
48:
2059-2065,
1999[Abstract].
35.
Ren, J,
Samson WK,
and
Sowers JR.
Insulin-like growth factor I as a cardiac hormone: physiological and pathophysiological implications in heart disease.
J Cell Mol Cardiol
31:
2049-2061,
1999.
36.
Ren, J,
Walsh MF,
Hamaty M,
Sowers JR,
and
Brown RA.
Altered inotropic response to IGF-I in diabetic rat heart: influence of intracellular Ca2+ and NO.
Am J Physiol Heart Circ Physiol
275:
H823-H830,
1998
37.
Russell-Jones, DL,
Bates AT,
Umpleby AM,
Hennessy TR,
Bowes SB,
Hopkins KD,
Jackson N,
Kelly J,
Shojaee-Moradie F,
Jones RH,
and
Sonksen PH.
A comparison of the effects of IGF-I and insulin on glucose metabolism, fat metabolism and the cardiovascular system in normal human volunteers.
Eur J Clin Invest
25:
403-411,
1995[ISI][Medline].
38.
Samarel, AM.
IGF-I overexpression rescues the failing heart.
Circ Res
90:
631-633,
2002
39.
Simpson, HL,
Umpleby AM,
and
Russell-Jones DL.
Insulin-like growth factor-I and diabetes. A review.
Growth Hormone IGF Res
8:
83-95,
1998[Medline].
40.
Sowers, JR,
and
Epstein M.
Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update.
Hypertension
26:
869-879,
1995
41.
Touyz, RM,
and
Schiffrin EL.
Growth factors mediate intracellular signaling in vascular smooth muscle cells through protein kinase C-linked pathways.
Hypertension
30:
1440-1447,
1997
42.
Vestergaard, H,
Rossen M,
Urhammer SA,
Muller J,
and
Pedersen O.
Short- and long-term metabolic effects of recombinant human IGF-I treatment in patients with severe insulin resistance and diabetes mellitus.
Eur J Endocrinol
136:
475-482,
1997[ISI][Medline].
43.
Wang, DW,
Kiyosue T,
Shigematsu S,
and
Arita M.
Abnormalities of K+ and Ca2+ currents in ventricular myocytes from rats with chronic diabetes.
Am J Physiol Heart Circ Physiol
269:
H1288-H1296,
1995
44.
Wold, LE,
Relling DP,
Colligan PB,
Scott GI,
Hintz KK,
Ren BH,
Epstein PN,
and
Ren J.
Characterization of excitation-contraction coupling in diabetic hypertensive cardiomyopathy in adult rat ventricular myocytes.
J Mol Cell Cardiol
33:
1719-1726,
2001[ISI][Medline].
45.
Zapf, J,
Schmid C,
Guler HP,
Waldvogel M,
Hauri C,
Futo E,
Hossenlopp P,
Binoux M,
and
Froesch ER.
Regulation of binding proteins for insulin-like growth factors (IGF) in humans. Increased expression of IGF binding protein 2 during IGF I treatment of healthy adults and in patients with extrapancreatic tumor hypoglycemia.
J Clin Invest
86:
952-961,
1990[ISI][Medline].
46.
Zenobi, PD,
Graf S,
Ursprung H,
and
Froesch ER.
Effects of insulin-like growth factor-I on glucose tolerance, insulin levels, and insulin secretion.
J Clin Invest
89:
1908-1913,
1992[ISI][Medline].